Clinical trials: Primary Angioplasty
Acute Myocardial Infarction
Bivalirudin in Acute Myocardial Infarction
The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES. This is a prospective, randomized, single-blind, active drug controlled multicenter clinical research and the study would…
- Trial name
- NCT02897037
- Testing
- Bivalirudin, heparin
- Where
- China
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Stenosis, Occlusion
Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions
Patients with peripheral artery disease will be treated with either drug coated balloon catheter, drug coated stent or uncoated stent.
- Conditions
- Stenosis, Occlusion, Restenosis
- Trial name
- SPORTS (NCT03332264)
- Testing
- SeQuent Please OTW, Eluvia Vascular Stent System, Nitinol stent
- Where
- 10 sites in Austria, Germany
- Volunteers
- 224 people
- Sponsor
- InnoRa GmbH
Myocardial Ischemia, Coronary Disease
Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury
The purpose of the study is to evaluate whether FX06 is capable of limiting infarct size following balloon catheterization for acute myocardial infarction.
- Conditions
- Myocardial Ischemia, Coronary Disease, Myocardial Infarction
- Trial name
- NCT00326976
- Testing
- FX06, Percutaneous coronary intervention
- Where
- 32 sites in Austria, Belgium and 9 more
- Volunteers
- 234 people
- Sponsor
- Fibrex Medical Research & Development GmbH
Myocardial Infarction
Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce the damage to the muscle that occurs with a heart attack.
- Trial name
- NCT00093197
- Testing
- KAI-9803 for Injection
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- KAI Pharmaceuticals
Chronic Coronary Occlusion, Left Main Coronary Artery Disease
EXCEL Clinical Trial (Universal Registry)
The purpose of the Universal Registry is to assess the proportion and reasons for which subjects with angiographically significant ULMCA disease requiring revascularization during the time course of this study are not randomized…
- Conditions
- Chronic Coronary Occlusion, Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease
- Trial name
- EXCEL (NCT01205789)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Anterior Wall Acute Myocardial Infarction
Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)
The primary objective of the study is to collect confirmatory data supporting the safety and effectiveness of SSO2 Therapy in treatment of anterior acute myocardial infarction (AMI) patients who have undergone successful…
- Trial name
- IC-HOT (NCT02603835)
- Testing
- SSO2 Therapy
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- TherOx
Acute Myocardial Infarction
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.
- Trial name
- NCT00271765
- Testing
- INO-1001
- Where
- 16 sites in United States, Israel
- Volunteers
- 40 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Anterior Wall Acute Myocardial Infarction
Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA).
- Trial name
- NCT01630707
- Testing
- SuperSaturated Oxygen (SS02) Therapy
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- TherOx
Coronary Disease, Myocardial Infarction
A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration.
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Diseases, Vascular Diseases
- Trial name
- CEL-02 (NCT04284995)
- Testing
- RUC-4 Compound
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- CeleCor Therapeutics